


9-8-06

Pat



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Eric J. Benjamin; Reinhardt B. Baudy, and
Michael R. Brandt

Confirmation No.: 7245

Application No.: 10/820,215

Group Art Unit: 1624

Filing Date: April 7, 2004

Examiner: Brenda Libby Coleman

For: Pharmaceutical Compositions for Intranasal Administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] Phosphonic Acid and Derivatives and Methods of Use Thereof

EXPRESS MAIL LABEL NO: EV 765639882 US
DATE OF DEPOSIT: September 6, 2006

EV765639882US

MS Amendment MS AF

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

REPLY TRANSMITTAL LETTER

- A Preliminary Amendment.
- A Reply Responsive to the Office Action Dated June 1, 2006.
- A Reply Supplemental to the Paper filed
- A Substitute Specification (pages 1 -) in clean form.
 - A substitute specification (pages 1 -) with markings.
- An Abstract is enclosed.
- replacement sheets of drawings are enclosed comprising figures
- Request is hereby made to accept black and white photograph(s) in this case, as they are the only practicable medium for illustrating the claimed invention. One (1) set of black and white photographs comprising figure(s) is submitted herewith.
- Petition is hereby made to accept drawing(s)/photograph(s) in this case.

- Three (3) sets of color drawing(s)/photograph(s) and black and white photocopy that accurately depicts to the extent possible, the subject matter shown in the color drawing(s)/photograph(s), are enclosed, comprising figures
- An amendment to the first paragraph in that portion of the Brief Description of the Drawings is also enclosed herewith advising that the patent contains at least one drawing/photograph in color.
- A Certified Copy of each of the following applications: is enclosed.
- An Assignee Power of Attorney is enclosed.
- Information Disclosure Statement.
 - Attached Form 1449.
 - A copy of each reference as listed on the attached Form PTO-1449 is enclosed herewith.
- A Terminal Disclaimer is attached.
- Appendices as follows: a copy of Trujillo Abstract; copies of The NMDA receptor complex; a long and winding road to therapeutics reference; Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia reference; Glutamate and anxiety reference; NMDA receptors as targets for drug action in neuropathic pain reference; N-methyl-D-aspartate receptor (NMDA) antagonists as potential pain therapeutics reference; Excitatory amino acid antagonists and their potential for the treatment of ischaemic brain damage in man reference.
- Other
- No Additional Fee is Due.**
- Applicant(s) has previously claimed small entity status under 37 CFR § 1.27.
- Applicant(s) by its/their undersigned attorney, claims small entity status under 37 CFR § 1.27 as
- This application is no longer entitled to small entity status. It is requested that this be noted in the files of the U.S. Patent and Trademark Office.



DOCKET NO.: AM101252/WYNC-2133


PATENT

			SMALL ENTITY		NOT SMALL ENTITY		
	REMAINING AFTER AMENDMENT	HIGHEST PAID FOR	EXTRA	RATE	Fee	RATE	Fee
TOTAL CLAIMS	56	56 (20 MINIMUM)	0	\$25 EACH	\$	\$50 EACH	\$0
INDEP. CLAIMS	4	4 (3 MINIMUM)	0	\$100 EACH	\$	\$200 EACH	\$0
FIRST PRESENTATION OF MULTIPLE DEPENDENT				\$180	\$	\$360	\$0
<input checked="" type="checkbox"/> ONE MONTH EXTENSION OF TIME				\$60	\$	\$120	\$120.00
<input type="checkbox"/> TWO MONTH EXTENSION OF TIME				\$225	\$	\$450	\$0
<input type="checkbox"/> THREE MONTH EXTENSION OF TIME				\$510	\$	\$1020	\$0
<input type="checkbox"/> FOUR MONTH EXTENSION OF TIME				\$795	\$	\$1590	\$0
<input type="checkbox"/> FIVE MONTH EXTENSION OF TIME				\$1080	\$	\$2160	\$0
<input type="checkbox"/> LESS ANY EXTENSION FEE ALREADY PAID				minus	(\$)	minus	(\$0)
<input type="checkbox"/> TERMINAL DISCLAIMER				\$65	\$	\$130	\$0
<input type="checkbox"/> OTHER FEE OR SURCHARGE AS FOLLOWS:							
TOTAL FEE DUE				\$			\$120.00

- A check in the amount of .00 is attached. Please charge any deficiency or credit any overpayment to Deposit Account 23-3050.
- Please charge Deposit Account No. 23-3050 in the amount of \$120.00. This sheet is attached in duplicate.
- The Commissioner is hereby authorized to charge any deficiency or credit any overpayment of the fees associated with this communication to Deposit Account No. 23-3050.
- Petition is hereby made under 37 CFR § 1.136(a) (fees: 37 CFR § 1.17(a)(1)-(4)) to extend the time for response to the Office Action of June 1, 2006 to and through October 1, 2006 comprising an extension of the shortened statutory period of 1 months.

The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to Deposit Account 23-3050. This sheet is provided in duplicate.

Date: September 6, 2006



Wendy A. Choi
Registration No. 36,697

Woodcock Washburn LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 2006 WW